Autolus Therapeutics (AUTL) to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Autolus Therapeutics to Receive $70 Million in Milestone Payments from Blackstone Life Sciences
December 8, 2022 4:03 PM ESTDevelopment milestone of $35m achieved earlier than anticipated as a result of the positive interim analysis of Autolus pivotal FELIX Phase 2 trial, announced in a separate press release today
Manufacturing milestone of $35m achieved as a result of completion of planned activities supporting the performance and qualification of the obecabtagene autoleucel (obe-cel) manufacturing process
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announces that Blackstone... More
Autolus Therapeutics announces pivotal Phase 2 FELIX clinical trial has met primary endpoint at interim analysis
December 8, 2022 4:02 PM ESTObe-cel demonstrated Overall Remission Rate (ORR) of 70% in interim analysis of 50 patients with relapsed/refractory (r/r) adult Acute Lymphoblastic Leukemia (ALL)
Encouraging safety data observed, with 3% Grade 3 Cytokine Release Syndrome (CRS) and 8% Grade 3 Immune effector cell-associated neurotoxicity syndrome (ICANS) in 92 patients treated Achievement of development milestone has triggered payment of $35m from Blackstone Life Sciences, announced in a separate press release todayThe trial has completed screening patients for entry into the morphological cohort
LONDON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq:... More
